Navigation Links
Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results

CAMBRIDGE, Mass., April 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the first quarter ended March 31, 2008. At March 31, 2008, Idenix's cash, cash equivalents and marketable securities totaled approximately $99.0 million.

2008 Year-to-Date Business Highlights

-- Idenix reported positive data from an ongoing phase I/II study of

IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being

developed for the treatment of HIV-1. In the first dosing cohort of

this study, eight HIV-1 infected treatment-naive patients receiving 800

mg of IDX899 once-daily achieved a median reduction in plasma virus

levels of approximately 2.0 log10, or 99 percent, after seven days of

treatment. The 400 mg cohort of this study is now complete and dosing

has been initiated in the 200 mg cohort. To date, no serious adverse

events have been reported and no patients have discontinued from the

study. Data from this clinical trial have been submitted for

presentation at scientific meetings this summer.

-- The company continued to make progress with its hepatitis C discovery

and development programs, having presented data from preclinical

studies of its lead nucleotide prodrug candidate, IDX184, and potential

clinical candidates from its protease inhibitor program at the annual

meeting of the European Association for the Study of the Liver (EASL)

last week. (Please see Idenix press release dated April 23, 2008 for

more information regarding the EASL presentations.)

-- The lead clinical candidate from the nucleotide prodrug program,

IDX184, is on track for an investigational new drug (IND)

application submission in the first half of 2008. Based on the

preclinical pharmacology and toxicology profile of IDX184

demonstrated to date, the company anticipates that the first-in-

man clinical trial should be initiated in the second half of


-- Idenix also reported positive preclinical data from its HCV

protease inhibitor program, with internally discovered compounds

exhibiting potency in the HCV replicon system and good

pharmacokinetic profiles in several animal species.

"We have made significant progress in the last six months in the discovery and development of our HCV and HIV programs," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "We are very pleased with the initial antiviral activity and safety data generated in the IDX899 clinical development program. Based on the profile of IDX899 exhibited to date, we believe that IDX899 could play an important role in the treatment of patients with HIV."

Sommadossi continued, "Our expertise and focus on antiviral discovery and development enables us to rapidly advance our programs through IND-enabling preclinical studies, proof-of-concept testing and into phase II clinical studies. With a comprehensive HCV discovery program in each of the major classes of direct-acting HCV antivirals, we are uniquely positioned to be one of the first companies to develop our own specifically targeted antiviral therapy for HCV (STAT-C)."

For the first quarter ended March 31, 2008, Idenix reported total revenues of $2.0 million, compared with total revenues of $24.8 million in the first quarter of 2007. The reduction in total revenues for the first quarter of 2008 as compared to the first quarter of 2007 was due to a decline of approximately $12.0 million in reimbursements of research and development costs from Novartis and the lack of receipt of milestone payments during the first quarter of 2008. Total revenues for the first quarter of 2008 consisted primarily of the amortization of upfront fees associated with development programs licensed by Novartis and royalties associated with worldwide sales of Tyzeka(R)/Sebivo(R) (telbivudine). Idenix reported a net loss of $20.5 million, or a loss of $0.36 per basic and diluted share, for the first quarter ended March 31, 2008, compared to a net loss of $11.6 million, or a loss of $0.21 per basic and diluted share, for the first quarter ended March 31, 2007.

2008 Financial Guidance

The company continues to expect to end 2008 with approximately $50.0 million of cash, cash equivalents and marketable securities, assuming no milestone payments, license fees, reimbursement for development programs, and no financing activities during 2008.

Conference Call Information

Idenix will hold a conference call today at 8:30 a.m. ET. To access the call please dial 800-471-3635 U.S./Canada 706-758-9475 International and enter conference identification number 43988689 or to listen to a live webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at Please log in approximately 10 minutes before the call to ensure a timely connection. An archived webcast will be available on the Idenix website for two weeks after the call. A replay of the call will also be available. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter the passcode 43988689.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and HIV. For further information about Idenix, please refer to

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "expect," "plans," "anticipates," "will," or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates and expectations with respect to additional milestone payments and cash balances at the end of 2008. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that historical sales of Tyzeka/Sebivo will in any way suggest future royalty payments or royalty rates owed to the company, or that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.





Three Months Ended

March 31,

2008 2007


Collaboration revenue - related party $2,031 $24,351

Other revenue 13 455

Total revenues 2,044 24,806

Operating expenses (1):

Cost of sales 395 70

Research and development 14,868 22,554

Selling, general and administrative 8,321 15,840

Restructuring charges 260 ----

Total operating expenses 23,844 38,464

Loss from operations (21,800) (13,658)

Investment and other income, net 939 1,978

Loss before income taxes (20,861) (11,680)

Income tax benefit 401 111

Net loss $(20,460) $(11,569)

Basic and diluted net loss per share: ($0.36) ($0.21)

Shares used in calculation of basic and diluted

net loss per share: 56,274 56,126

(1) Stock-based compensation expenses included in

operating expenses amounted to approximately:

Research and development $660 $1,168

Selling, general and administrative 880 1,237





March 31, December 31,

2008 2007


Cash and cash equivalents $54,613 $48,260

Marketable securities 30,947 39,862

Receivables from related party 940 11,196

Other current assets 3,440 4,401

Total current assets 89,940 103,719

Intangible assets, net 13,258 13,548

Property and equipment, net 15,146 15,461

Marketable securities, non-current 13,330 23,882

Other assets 3,901 3,930

Total assets $135,575 $160,540


Accounts payable and accrued expenses $17,440 $21,809

Deferred revenue, related party 8,193 8,372

Other current liabilities 486 553

Total current liabilities 26,119 30,734

Long-term obligations 18,073 19,107

Deferred revenue, related party, net of current 38,916 41,861

position 83,108 91,702

Total liabilities 52,467 68,838

Stockholders' equity

Total liabilities and stockholders' equity $135,575 $160,540

Idenix Pharmaceuticals Contact:

Teri Dahlman (617) 995-9905

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
2. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
3. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Post Your Comments:
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... April 29, 2017 , ... Saturday, April 29, ... positive impact veterinarians have on animal health and welfare as well as on ... Health (OIE) choose a theme each year and this year have selected “Antimicrobial ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... It's ... there are a number of illnesses that are unclear as to whether or not ... their heads. Bronchitis is one of these illnesses. So, FindaTopDoc took a look into ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Getting enough sleep affects much more than energy ... going just 19 hours without sleep can compromise motor reaction time, which can increase the ... Amica Insurance is sharing the following tips from the NSF to help you sleep better ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... National Harbor, Md. (PRWEB) , ... April 28, ... ... Urgent Care Association of America (UCAOA) and College of Urgent Care Medicine will ... Momentum 2017 workshops, sessions and speakers will help those in the industry adapt ...
Breaking Medicine News(10 mins):